Dreamboat sinks MannKind’s latest US Afrezza effort
The US FDA has rejected MannKind’s inhaled insulin Afrezza and called for more clinical trials to prove the product’s “Dreamboat” delivery tech is comparable to the MedTone device used in earlier studies.